SVB Leerink Raises Moderna (NASDAQ:MRNA) Price Target to $77.00

Moderna (NASDAQ:MRNAGet Rating) had its price target upped by equities research analysts at SVB Leerink from $70.00 to $77.00 in a note issued to investors on Monday, Marketbeat reports. The firm presently has an “underperform” rating on the stock. SVB Leerink’s price target points to a potential downside of 52.12% from the stock’s current price.

Several other equities research analysts have also commented on the stock. Morgan Stanley upped their price target on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. Piper Sandler reduced their price target on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a research report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus price target of $228.58.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $160.81 on Monday. Moderna has a fifty-two week low of $115.61 and a fifty-two week high of $497.49. The business has a 50-day simple moving average of $149.27 and a two-hundred day simple moving average of $152.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77. The firm has a market cap of $63.96 billion, a price-to-earnings ratio of 4.73, a price-to-earnings-growth ratio of 0.93 and a beta of 1.61.

Moderna (NASDAQ:MRNAGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $8.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.18 by $3.40. Moderna had a return on equity of 121.86% and a net margin of 64.77%. The business had revenue of $6.07 billion during the quarter, compared to analyst estimates of $4.43 billion. During the same quarter in the previous year, the firm earned $2.84 EPS. Moderna’s revenue was up 213.2% on a year-over-year basis. On average, analysts expect that Moderna will post 27.17 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $161.00, for a total value of $1,610,000.00. Following the completion of the sale, the director now directly owns 2,477,209 shares of the company’s stock, valued at approximately $398,830,649. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, insider Juan Andres sold 195 shares of the company’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $133.71, for a total value of $26,073.45. Following the completion of the transaction, the insider now directly owns 9,309 shares in the company, valued at approximately $1,244,706.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Noubar Afeyan sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $161.00, for a total value of $1,610,000.00. Following the completion of the transaction, the director now owns 2,477,209 shares of the company’s stock, valued at $398,830,649. The disclosure for this sale can be found here. In the last ninety days, insiders sold 554,029 shares of company stock valued at $82,263,545. 17.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Field & Main Bank bought a new position in shares of Moderna during the 4th quarter valued at approximately $25,000. Confluence Wealth Services Inc. bought a new position in shares of Moderna during the 4th quarter valued at approximately $25,000. Standard Family Office LLC bought a new position in shares of Moderna during the 4th quarter valued at approximately $25,000. Total Clarity Wealth Management Inc. bought a new position in shares of Moderna during the 2nd quarter valued at approximately $25,000. Finally, AllSquare Wealth Management LLC bought a new position in shares of Moderna during the 1st quarter valued at approximately $26,000. 61.20% of the stock is currently owned by institutional investors.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.